Buy RCEL by Aug 15, 2026.

The interesting part is that this isn’t some pre-revenue biotech hoping for approval someday. They already have FDA-approved technology being used in burns and trauma care, and they’re expanding the platform into broader wound applications. The market basically punished the stock after reimbursement disruptions and slower-than-expected adoption, but revenue is still growing and the valuation now looks compressed compared to many med-tech peers. Things I’m watching: Whether cash burn drops over the next few quarters Continued reimbursement stabilization Adoption of …